SUBSCRIBE
SUBSCRIBE
News   FDA

US FDA Staff Questions Cell Therapeutics, Inc. Lymphoma Drug Pixantrone Data

February 8, 2010 | 
1 min read
Bookmark and Share

Reuters -- U.S. drug reviewers questioned effectiveness data from Cell Therapeutics Inc (CTIC.O) for an experimental lymphoma drug and said the medicine carried substantial side effects, according to documents released on Monday.
FDA Approvals Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Two arrow signs representing the new way and old way approach to business
Regulatory
Atara Climbs Amid Report of FDA Inconsistency Leading to Cell Therapy’s Rejection
February 26, 2026
 · 
1 min read
 · 
Tristan Manalac
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
Regulatory
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
February 25, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
February 25, 2026
 · 
2 min read
 · 
Heather McKenzie
Capitol Hill COVID-19 blood testing, abstract virus testing during pandemic concept, State Building Washington DC, USA, 3d illustration
FDA
Opinion: Balancing Safety Access in Rare Disease—Lessons From Sarepta
February 25, 2026
 · 
6 min read
 · 
Joshua R. Mansbach